358 related articles for article (PubMed ID: 35456503)
21. Reclassifying BRCA1 c.4358-2A > G and BRCA2 c.475 + 5G > C variants from "Uncertain Significance" to "Pathogenic" based on minigene assays and clinical evidence.
Ning Y; Zhang Y; Tian T; Chen Y; Wang J; Lei K; Cui Z
J Cancer Res Clin Oncol; 2024 Feb; 150(2):62. PubMed ID: 38300310
[TBL] [Abstract][Full Text] [Related]
22. Comparable frequency of BRCA1, BRCA2 and TP53 germline mutations in a multi-ethnic Asian cohort suggests TP53 screening should be offered together with BRCA1/2 screening to early-onset breast cancer patients.
Lee DS; Yoon SY; Looi LM; Kang P; Kang IN; Sivanandan K; Ariffin H; Thong MK; Chin KF; Mohd Taib NA; Yip CH; Teo SH
Breast Cancer Res; 2012 Apr; 14(2):R66. PubMed ID: 22507745
[TBL] [Abstract][Full Text] [Related]
23. Expansion of Cancer Risk Profile for BRCA1 and BRCA2 Pathogenic Variants.
Momozawa Y; Sasai R; Usui Y; Shiraishi K; Iwasaki Y; Taniyama Y; Parsons MT; Mizukami K; Sekine Y; Hirata M; Kamatani Y; Endo M; Inai C; Takata S; Ito H; Kohno T; Matsuda K; Nakamura S; Sugano K; Yoshida T; Nakagawa H; Matsuo K; Murakami Y; Spurdle AB; Kubo M
JAMA Oncol; 2022 Jun; 8(6):871-878. PubMed ID: 35420638
[TBL] [Abstract][Full Text] [Related]
24. Sensitivity of BRCA1/2 testing in high-risk breast/ovarian/male breast cancer families: little contribution of comprehensive RNA/NGS panel testing.
Byers H; Wallis Y; van Veen EM; Lalloo F; Reay K; Smith P; Wallace AJ; Bowers N; Newman WG; Evans DG
Eur J Hum Genet; 2016 Nov; 24(11):1591-1597. PubMed ID: 27273131
[TBL] [Abstract][Full Text] [Related]
25. Prevalence of BRCA1 and BRCA2 pathogenic sequence variants in ovarian cancer patients in the Gulf region: the PREDICT study.
Azribi F; Abdou E; Dawoud E; Ashour M; Kamal A; Al Sayed M; Burney I
BMC Cancer; 2021 Dec; 21(1):1350. PubMed ID: 34930165
[TBL] [Abstract][Full Text] [Related]
26. Pathogenic germline variants in non-BRCA1/2 homologous recombination genes in ovarian cancer: Analysis of tumor phenotype and survival.
Kahn RM; Selenica P; Boerner T; Roche KL; Xiao Y; Sia TY; Maio A; Kemel Y; Sheehan M; Salo-Mullen E; Breen KE; Zhou Q; Iasonos A; Grisham RN; O'Cearbhaill RE; Chi DS; Berger MF; Kundra R; Schultz N; Ellenson LH; Stadler ZK; Offit K; Mandelker D; Aghajanian C; Zamarin D; Sabbatini P; Weigelt B; Liu YL
Gynecol Oncol; 2024 Jan; 180():35-43. PubMed ID: 38041901
[TBL] [Abstract][Full Text] [Related]
27. Reanalysis of BRCA1/2 negative high risk ovarian cancer patients reveals novel germline risk loci and insights into missing heritability.
Stafford JL; Dyson G; Levin NK; Chaudhry S; Rosati R; Kalpage H; Wernette C; Petrucelli N; Simon MS; Tainsky MA
PLoS One; 2017; 12(6):e0178450. PubMed ID: 28591191
[TBL] [Abstract][Full Text] [Related]
28. Frequency and spectrum of founder and non-founder BRCA1 and BRCA2 mutations in a large series of Russian breast cancer and ovarian cancer patients.
Sokolenko AP; Sokolova TN; Ni VI; Preobrazhenskaya EV; Iyevleva AG; Aleksakhina SN; Romanko AA; Bessonov AA; Gorodnova TV; Anisimova EI; Savonevich EL; Bizin IV; Stepanov IA; Krivorotko PV; Berlev IV; Belyaev AM; Togo AV; Imyanitov EN
Breast Cancer Res Treat; 2020 Nov; 184(1):229-235. PubMed ID: 32776218
[TBL] [Abstract][Full Text] [Related]
29. High prevalence of deleterious BRCA1 and BRCA2 germline mutations in arab breast and ovarian cancer patients.
Alhuqail AJ; Alzahrani A; Almubarak H; Al-Qadheeb S; Alghofaili L; Almoghrabi N; Alhussaini H; Park BH; Colak D; Karakas B
Breast Cancer Res Treat; 2018 Apr; 168(3):695-702. PubMed ID: 29297111
[TBL] [Abstract][Full Text] [Related]
30. Double Heterozygosity for Rare Deleterious Variants in the
Madar L; Majoros V; Szűcs Z; Nagy O; Babicz T; Butz H; Patócs A; Balogh I; Koczok K
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37895014
[TBL] [Abstract][Full Text] [Related]
31. Pancreatic acinar cell carcinoma is associated with
Kryklyva V; Haj Mohammad N; Morsink FHM; Ligtenberg MJL; Offerhaus GJA; Nagtegaal ID; de Leng WWJ; Brosens LAA
Cancer Biol Ther; 2019; 20(7):949-955. PubMed ID: 31002019
[TBL] [Abstract][Full Text] [Related]
32. Prevalence and spectrum of BRCA germline variants in mainland Chinese familial breast and ovarian cancer patients.
Kim YC; Zhao L; Zhang H; Huang Y; Cui J; Xiao F; Downs B; Wang SM
Oncotarget; 2016 Feb; 7(8):9600-12. PubMed ID: 26848529
[TBL] [Abstract][Full Text] [Related]
33. Molecular Genetic Characteristics of
Fierheller CT; Alenezi WM; Serruya C; Revil T; Amuzu S; Bedard K; Subramanian DN; Fewings E; Bruce JP; Prokopec S; Bouchard L; Provencher D; Foulkes WD; El Haffaf Z; Mes-Masson AM; Tischkowitz M; Campbell IG; Pugh TJ; Greenwood CMT; Ragoussis J; Tonin PN
Genes (Basel); 2023 Jan; 14(2):. PubMed ID: 36833203
[No Abstract] [Full Text] [Related]
34. Deleterious somatic variants in 473 consecutive individuals with ovarian cancer: results of the observational AGO-TR1 study (NCT02222883).
Hauke J; Hahnen E; Schneider S; Reuss A; Richters L; Kommoss S; Heimbach A; Marmé F; Schmidt S; Prieske K; Gevensleben H; Burges A; Borde J; De Gregorio N; Nürnberg P; El-Balat A; Thiele H; Hilpert F; Altmüller J; Meier W; Dietrich D; Kimmig R; Schoemig-Markiefka B; Kast K; Braicu E; Baumann K; Jackisch C; Park-Simon TW; Ernst C; Hanker L; Pfisterer J; Schnelzer A; du Bois A; Schmutzler RK; Harter P
J Med Genet; 2019 Sep; 56(9):574-580. PubMed ID: 30979843
[TBL] [Abstract][Full Text] [Related]
35. Prevalence and Spectrum of
Foglietta J; Ludovini V; Bianconi F; Pistola L; Reda MS; Al-Refaie A; Tofanetti FR; Mosconi A; Minenza E; Anastasi P; Molica C; Stracci F; Roila F
Genes (Basel); 2020 Aug; 11(8):. PubMed ID: 32806537
[TBL] [Abstract][Full Text] [Related]
36. Spectrum and characterisation of BRCA1 and BRCA2 deleterious mutations in high-risk Czech patients with breast and/or ovarian cancer.
Machackova E; Foretova L; Lukesova M; Vasickova P; Navratilova M; Coene I; Pavlu H; Kosinova V; Kuklova J; Claes K
BMC Cancer; 2008 May; 8():140. PubMed ID: 18489799
[TBL] [Abstract][Full Text] [Related]
37. BRCA1 and BRCA2 whole cDNA analysis in unsolved hereditary breast/ovarian cancer patients.
Montalban G; Bonache S; Bach V; Gisbert-Beamud A; Tenés A; Moles-Fernández A; López-Fernández A; Carrasco E; Balmaña J; Diez O; Gutiérrez-Enríquez S
Cancer Genet; 2021 Nov; 258-259():10-17. PubMed ID: 34237702
[TBL] [Abstract][Full Text] [Related]
38. Comprehensive profiling of BRCA1 and BRCA2 variants in breast and ovarian cancer in Chinese patients.
Gao X; Nan X; Liu Y; Liu R; Zang W; Shan G; Gai F; Zhang J; Li L; Cheng G; Song L
Hum Mutat; 2020 Mar; 41(3):696-708. PubMed ID: 31825140
[TBL] [Abstract][Full Text] [Related]
39. Whole-exome sequencing of ovarian cancer families uncovers putative predisposition genes.
Zhu Q; Zhang J; Chen Y; Hu Q; Shen H; Huang RY; Liu Q; Kaur J; Long M; Battaglia S; Eng KH; Lele SB; Zsiros E; Villella J; Lugade A; Yao S; Liu S; Moysich K; Odunsi KO
Int J Cancer; 2020 Apr; 146(8):2147-2155. PubMed ID: 31265121
[TBL] [Abstract][Full Text] [Related]
40. Analysis of the pathogenic variants of BRCA1 and BRCA2 using next-generation sequencing in women with familial breast cancer: a case-control study.
Zayas-Villanueva OA; Campos-Acevedo LD; Lugo-Trampe JJ; Hernández-Barajas D; González-Guerrero JF; Noriega-Iriondo MF; Ramírez-Sánchez IA; Martínez-de-Villarreal LE
BMC Cancer; 2019 Jul; 19(1):722. PubMed ID: 31331294
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
